An interventional study of Rocuronium 0.3 mg/kg and Rocuronium 0.6 mg/kg in Complication of Ventilation Therapy and Observation of Neuromuscular Block, sponsored by University of Rostock. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-05-03.
Sponsored by University of Rostock · Not applicable, Interventional, and Treatment
Mask ventilation during induction of anesthesia can be improved by administration of neuromuscular blocking agents (NMBAs). NMBAs are usually administered after testing mask ventilation; however, muscle relaxants may improve mask ventilation and they do not alter mask ventilation. Thus, growing evidence suggests to administer muscle relaxants before testing mask ventilation. We will study different dosages of rocuronium; we assume that higher dosages of rocuronium will improve mask ventilation compared with lower dosages.
Mask ventilation during induction of anesthesia can be improved by administration of neuromuscular blocking agents (NMBAs). NMBAs are usually administered after testing mask ventilation; however, muscle relaxants may improve mask ventilation and they do not alter mask ventilation. Thus, growing evidence suggests to administer muscle relaxants before testing mask ventilation.We will administer rocuronium 0.3 mg/kg, 0.6 mg/kg, 0.9 mg/kg and saline (placebo group) before starting with mask ventilation. We will grade mask ventilation based on various scores before and after rocuronium application. Afterwards patient's tracheas will be intubated. We assess risk factors for difficult mask ventilation.
We hypothesize that rocuronium 0.9 mg/kg will be superior to rocuronium 0.3 mg/kg and saline.
University of Rostock is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients receive rocuronium 0.3 mg/kg
Drug: Rocuronium 0.3 mg/kg
Patients receive rocuronium 0.6 mg/kg
Drug: Rocuronium 0.6 mg/kg
Patients receive rocuronium 0.9 mg/kg
Drug: Rocuronium 0.9 mg/kg
Patients receive saline
Drug: Placebo
Patients receive rocuronium 0.3 mg/kg
Also known as: Esmeron
Patients receive rocuronium 0.6 mg/kg
Also known as: Esmeron
Patients receive rocuronium 0.9 mg/kg
Also known as: Esmeron
Patients receive saline
Also known as: Saline
Incidence of improved mask ventilation after rocuronium administration
Graded with various scores
Time frame: Two minutes after rocuronium administration
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Rostock